Celldex Therapeutics Inc
NASDAQ:CLDX

Watchlist Manager
Celldex Therapeutics Inc Logo
Celldex Therapeutics Inc
NASDAQ:CLDX
Watchlist
Price: 24.65 USD -0.16% Market Closed
Market Cap: $1.6B

Wall Street
Price Targets

CLDX Price Targets Summary
Celldex Therapeutics Inc

Wall Street analysts forecast CLDX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLDX is 54.42 USD with a low forecast of 24.24 USD and a high forecast of 94.5 USD.

Lowest
Price Target
24.24 USD
2% Downside
Average
Price Target
54.42 USD
121% Upside
Highest
Price Target
94.5 USD
283% Upside
Celldex Therapeutics Inc Competitors:
Price Targets
0HQ1
Brooks Automation Inc
1% Upside
TCPC
BlackRock TCP Capital Corp
28% Upside

Revenue
Forecast

-2% / Year
Past Growth
119% / Year
Estimated Growth
Estimates Accuracy
16%
Average Beat
-2% / Year
Past Growth
119% / Year
Estimated Growth
Estimates Accuracy
16%
Average Beat

For the last 13 years the compound annual growth rate for Celldex Therapeutics Inc's revenue is -2%. The projected CAGR for the next 4 years is 119%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-88%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-88%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CLDX's stock price target?
Price Target
54.42 USD

According to Wall Street analysts, the average 1-year price target for CLDX is 54.42 USD with a low forecast of 24.24 USD and a high forecast of 94.5 USD.

What is Celldex Therapeutics Inc's Revenue forecast?
Projected CAGR
119%

For the last 13 years the compound annual growth rate for Celldex Therapeutics Inc's revenue is -2%. The projected CAGR for the next 4 years is 119%.

Back to Top